0107 vs Fredun Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how 0107 (0107) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: 0107 trades at MYR 0.11 versus a fair value of MYR 0.02 (-82%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
0107
0107.KLSE · MYR · Consumer Discretionary
-82%
upside to fair value
overvalued
PriceMYR 0.11
Fair ValueMYR 0.02
Quality33/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
0107Fredun Pharmaceuticals
Valuation
—P/E (TTM)42.2×
0.95×P/S (TTM)2.23×
0.64×P/B5.03×
3.5×EV/EBITDA15.5×
—Dividend yield0.0%
—Dividend per share₹0.70
Profitability
-119%Net margin5%
-64%Operating margin12%
—Return on equity16%
4%Return on assets9%
Growth
-9%Revenue growth (YoY)27%
78.3%Avg. growth/yr (3Y)32.2%
40.5%Avg. growth/yr (5Y)36.9%
Balance & size
—Debt / equity0.20×
$37MMarket cap$149M
expensiveGrowth qualityexpensive
0107 leads: 5 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
0107of which business quality 33 · market factors 26Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
10
48
Quality GrowthAre margins and returns improving?
83
73
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
64
16
Low VolatilityCalm price path (market factor)
24
43
MomentumPrice trend over the last 3–12 months (market factor)
23
39
52W MomentumDistance to the 52-week high (market factor)
34
54
Net IssuanceBuybacks instead of dilution
3
7
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
0107
Earnings-BasedMYR 0.01
MultiplesMYR 0.02
Asset-BasedMYR 0.03
Economic ProfitMYR 0.01
6 of 6 models see the stock below the current price.
Fredun Pharmaceuticals
Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535
5 of 14 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
0107
Bear MYR 0.01Fair Value MYR 0.02Bull MYR 0.03
MYR 0.11 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
0107 · Consumer Discretionary
Quality score33 · bottom 25%
Fair value upside-82% · bottom 25%
Fredun Pharmaceuticals · Healthcare
Quality score33 · bottom 25%
Fair value upside+77% · Top 25%
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: 0107 trades at MYR 0.11 versus a fair value of MYR 0.02 (-82%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Fredun Pharmaceuticals has the higher quality score (33/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
